PBMCs from MS patients treated with CTLA‐4 signaling peptide exhibited significantly increased CD25+ Foxp3+ regulatory T cells during their activation with TGF‐β and IL‐2 (Figure 6k,l; andTable S2, Supporting Information). This evidence concerns the gene FOXP3 and myeloid sarcoma.